(Q42260844)

English

Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.

scientific article published on September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Anthony M. Mills

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Calvin Cohen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Edwin Dejesus

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Cynthia Brinson

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Scott Williams

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Kitty L Yale

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Srini Ramanathan

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Maggie H Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Kirsten White

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Susan K Chuck

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Andrew K Cheng

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

1 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

216-223

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24144898%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Efavirenz: a decade of clinical experience in the treatment of HIV.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Neuropsychiatric side effects of efavirenz therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

1 reference

https://api.crossref.org/works/10.1310%2FHCT1405-216

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42260844&oldid=1568080371"